Denali Therapeutics, a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced that Dr. Dana Andersen has joined the company as Chief Technical and Manufacturing Officer.
Dr. Andersen joins Denali from Genentech, where he served in various roles for nearly 23 years, working most recently as Vice President and Global Head of Technical Development Project & Portfolio Management. Prior to this role, he was Vice President of Pharmaceutical Development and held numerous leadership roles spanning biologics manufacturing process development at Genentech.
Dr. Andersen is a fellow of the American Institute for Medical and Biological Engineering and received a B.S. from the University of Colorado at Boulder, and a M.S. and Ph.D. from Stanford University, all in chemical engineering with a focus on biological systems.
“I am thrilled to join Denali’s team to help advance a promising portfolio of small and large molecules addressing neurodegenerative disease,” said Dr. Andersen… Continue reading....